Investor Presentation

AI summary - Consolidated Q1FY27 revenue 2,545 Cr (+17.5% y-y); PAT 263 Cr (+3.6% y-y) - Hospital business revenue grew 19% to 2,187 Cr; operating EBITDA margin ~22% on like-for-like basis - Diagnostics business revenue grew 10.2% to 407 Cr; operating EBITDA margin improved to 23.9% - Occupancy stable at ~69%; ARPOB up 2.6% y-y - Net debt to EBITDA at 1.01x; net debt 2,233 Cr - Specialty mix growth: Renal +28%, Neurosciences +27%, Orthopedics +23% y-y - Digital channel revenues up 18.2%, contributing 29.2% of hospital revenues - International patient revenues up 13%, contributing 7.5% of hospital revenues - Agilus diagnostics conducted 10.46 mn tests, B2C:B2B mix 53:47 - Clinical excellence highlighted by advanced robotic surgeries and new centers of excellence